Factor IXa Inhibition Contributes to the Heparin Effect

Summary

We investigated whether the inactivation of factor IXa contributes to the partial inhibition of thrombin formation that is observed at therapeutic concentrations of heparin. The action of standard unfractionated heparin (0.05 U/ml) on thrombin formation in the intrinsic system was compared to that of a mixture of dermatan sulfate (DS) and a synthetic pentasaccharide (PS). DS enhances the action of heparin cofactor II which inhibits thrombin only. PS specifically enhances the anti-factor Xa activity of antithrombin III (AT III). The concentrations of DS and PS were chosen so as to obtain equal anti-thrombin and anti-factor Xa activities as in 0.05 U/ml heparin. An extra inhibitory effect of heparin over the mixture is observed in situations where free factor IXa, not bound to factor VIIIa and phospholipid, limits the rate of thrombin formation, notably in contact activated plasma. We conclude that the inactivation of free factor IXa by heparin contributes importantly to the inhibition of thrombin formation in the intrinsic system such as e.g. measured in the activated partial thromboplastin time.

• References

• 1 Rosenberg AD, Damus PS. The purification and the mechanism of action of human antithrombin-heparin cofactor. J Biol Chem 1973; 248: 6490-505
• 2 Holmer E, Kurachi K, Söderström G. The molecular weight dependence of the rate enhancing effect of heparin on the inhibition of thrombin, factor Xa, factor IXa, factor XIa, factor XIIa, or kallikrein by antithrombin. Biochem J 1981; 193: 395-400
• 3 Hemker HC. The mode of action of heparin in plasma. In: XIth Congress Thrombosis and Haemostasis, Brussels.. Verstraete M, Vermijlen J, Lynen HR, Arnout J. (eds) Leuven University Press, Leuven: 1987. pp 17-36
• 4 Béguin S, Lindhout T, Hemker HC. The mode of action of heparin in plasma. Thromb Haemostas 1988; 60: 457-62
• 5 Choay J, Petitou M, Lormeau JC, Sinay P, Casu BJ, Gatti G. Structure-activity relationship of heparin: a synthetic pentasaccharide with high affinity for antithrombin III and eliciting high anti-factor Xa activity. Biochem Biophys Res Commun 1983; 116: 492-9
• 6 McNeely TB, Griffith MJ. The anticoagulant mechanism of action of heparin in contact-plasma: Inhibition of factor X activation. Blood 1985; 65: 1226-31
• 7 Hemker HC, Willems G, Béguin S. A computer assisted method to obtain the prothrombin activation velocity in whole plasma independent of thrombin decay processes. Thromb Haemostas 1986; 56: 9-17
• 8 Ofosu FA, Sié P, Modi GJ, Fernandez F, Buchanan MC, Blajchman MA, Boneu B, Hirsh J. The inhibition of thrombin-dependent positive-feedback reaction is critical to the expression of the anticoagulant effect of heparin. Biochem J 1987; 243 (2) 579-88
• 9 Ofosu FA, Hirsh J, Esmon CT, Modi GJ, Smith LM, Anvari N, Buchanan MC, Fenton JW II, Blajchman MA. Unfractionated heparin inhibits thrombin-catalysed amplification reactions of coagulation more efficiently than those catalysed by factor Xa. Biochem J 1989; 257: 143-50
• 10 Parker KA, Tollefsen DM. The protease specificity of heparin cofactor II. Inhibition of thrombin generated during coagulation. J Biol Chem 1985; 260: 3501
• 11 Choay J, Lormeau JC, Petitou M, Sinaÿ P, Fareed J. Anti Xa active heparin oligosaccharides. Thromb Res 1980; 18: 573-8
• 12 Fujikawa K, Thompson AR, Legaz ME, Meyer RG, Davie EW. Isolation and characterization of bovine factor IX (Christmas factor). Biochemistry 1973; 12: 4938-45
• 13 Vehar GH, Davie EW. Preparation and properties of bovine factor VIII. Biochemistry 1980; 19: 401-10
• 14 Pletcher CH, Nelsestuen GI. The rate determining step of the heparin-catalyzed antithrombin-thrombin reaction is independent of thrombin. J Biol Chem 1982; 257: 5342-5
• 15 Owren PA, Aas K. The control of dicoumarol therapy and the quantitative determination of prothrombin and proconvertin. Scand J Clin Lab Invest 1951; 3: 201-18
• 16 Rosing J, Tans G, Govers-Riemslag JWP, Zwaal RFA, Hemker HC. The role of phospholipids and factor Va in the prothrombinase complex. J Biol Chem 1980; 255: 274-83
• 17 Teien AN, Lie M, Abildgaard U. Assay of heparin in plasma using a chromogenic substrate for activated factor X. Thromb Res 1976; 8: 413-6
• 18 Teien AN, Lie M. Evaluation of an amidolytic heparin assay method: Increased sensitivity by adding purified antithrombin III. Thromb Res 1977; 10: 399-410
• 19 Willems GM, Hemker HC. Mathematical analysis of the thrombin generation curve. Thromb Haemostas 1986; 56: 15-7
• 20 Ma Xi, Béguin S, Hemker HC. Importance of factor IX-dependent prothrombinase formation - the Josso pathway - in clotting plasma. Haemostasis 1989; 19: 301-308
• 21 Colman RW, Scott CF, Pixley RA, De La Cadena RA. Effect of heparin on the inhibition of the contact factor enzymes. Ann NY Acad Sci 1989; 556: 95-103